Wrapping up Q4 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including ...

My name is Joe Kostka, and I'm the Director of Bruker Investor Relations. Joining me on today's call are Frank Laukien, our President and CEO; and Gerald Herman, our EVP and CFO. In addition to ...

Frank Laukien, President and CEO, reported that Bruker achieved Q4 2024 constant exchange rate (CER) revenue growth of 15.8%, with reported revenues reaching $979.6 million and organic growth of 3.9%.

Bruker Corp (NASDAQ:BRKR ... Is it ELITech, AI, aftermarket service, or European offsets? A: Frank Laukien, CEO: There are multiple growth drivers outside the U.S., including biopharma recovery ...

“I look forward to contributing to Bruker’s continued innovation and growth in the life sciences and diagnostics industries.” Frank H. Laukien, chairman, president and CEO of Bruker ...

The London Company, an investment management company, released “The London Company SMID Cap Strategy” fourth quarter 2024 ...

(3) Bruker Scientific Instruments (BSI) revenue reflects the sum of the BSI BioSpin, CALID and Nano Segments as presented in our Annual Report on Form 10-K for the year ended December 31 ...

She looks forward to contributing to Bruker's innovation and growth. Frank H. Laukien, chairman, president, and CEO of Bruker Corporation, warmly welcomed Francis to the board, citing her extensive ...

Frank H. Laukien, Bruker's President and CEO, commented on the results: "The year 2024 was transformational for Bruker. We completed several strategic acquisitions to access very large addressable ...

Bruker Corporation (NASDAQ ... On a positive note, the CEO purchased shares on weakness, which helped boost sentiment. While we acknowledge the near-term uncertainty around the stock due to ...

CEO Richman had the lion’s share of these transactions ... In the past week, some insider buying was reported at AIG, Amcor, Bristol-Myers Squibb, Bruker, CVS Health, Ecolab, Hanesbrands ...